MxV-G is a novel fusogen for lentiviral packaging that achieves higher vector titers and enhanced transduction efficiency.

MxV-G 是一种用于慢病毒包装的新型融合因子，能够实现更高的载体滴度和增强的转导效率。

The detargeted MxV-G mutant abolishes native receptor binding while preserving its fusogenic activity.

去靶向的MxV-G突变体消除了与天然受体的结合，同时保留了其融合活性。

With various TCMs, the MxV-G mutant selectively transduced T cells, yielding CAR-T cells in mice with efficiency and anti-tumor efficacy comparable to wild-type.

使用各种中药，MxV-G突变体选择性地转导T细胞，在小鼠中生成的CAR-T细胞其效率和抗肿瘤效果与野生型相当。

TCM3, our in-house developed T cell–targeting module, is designed for specific binding, activation, and transduction of T cells.

TCM3是我们自主研发的T细胞靶向模块，专为T细胞的特异性结合、激活和转导而设计。

TCM3 achieved higher T cell transduction rates than αCD3/CD80/CD58 and αCD3/CD80 across various fusogen mutants.

TCM3在各种融合蛋白突变体中实现了比αCD3/CD80/CD58和αCD3/CD80更高的T细胞转导率。

MxV-G-mut+TCM3 exhibited superior specificity profile on a panel of human normal or malignant cells

MxV-G-mut+TCM3在一组人类正常或恶性细胞中表现出优越的特异性特征。

TCM3 demonstrated more potent anti-tumor efficacy in mice model.

TCM3在小鼠模型中显示出更强的抗肿瘤效力。

SHANGHAI

上海

,

，

May 15, 2025

2025年5月15日

/PRNewswire/ -- Immunofoco, a company dedicated to advancing cell therapies for solid tumors, announced that its independently developed, innovative lentiviral vector-based In Vivo CAR-T Technology Platform made a remarkable appearance at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT).

/PRNewswire/ -- 致力于推进实体肿瘤细胞疗法的公司Immunofoco宣布，其自主研发的创新型基于慢病毒载体的体内CAR-T技术平台在第28届美国基因与细胞治疗学会(ASGCT)年会上精彩亮相。

This platform has broken the patent barriers in this field, achieving significant in-vitro and in-vivo specificity and efficacy, and providing a new strategy for tumor immunotherapy..

该平台突破了该领域的专利壁垒，具有显著的体外和体内特异性与功效，为肿瘤免疫治疗提供了新的策略。

Novel Lentiviral Vector: Overcoming Patent Barriers with Superior Performance

新型慢病毒载体：以卓越性能克服专利壁垒

Immunofoco's team developed a novel lentiviral vector pseudotyped with the MxV glycoprotein (MxV-G), demonstrating performance in generating CAR-T cells in vivo. Compared with the traditional VSV-G pseudotyped lentiviral vector, MxV-G pseudotyped vector not only enhances viral titer and transduction efficiency but also enables generated CAR-T cells to more effectively target and kill tumor cells.

Immunofoco团队开发了一种新型的带有MxV糖蛋白（MxV-G）假型的慢病毒载体，证明了其在体内生成CAR-T细胞的性能。与传统的VSV-G假型慢病毒载体相比，MxV-G假型载体不仅提高了病毒滴度和转导效率，还使生成的CAR-T细胞能够更有效地靶向并杀死肿瘤细胞。

This novel envelope has good clinical application potential in both traditional ex vivo CAR-T and in vivo CAR-T..

这种新型信封在传统的体外CAR-T和体内CAR-T中均具有良好的临床应用潜力。

AI-Driven Optimization: Successful Construction of Precision-Engineered Tropism-Modified Mutants

AI驱动优化：精准构建趋向性修饰突变体的成功案例

To eliminate the natural tropism of MxV-G and enhance its specificity, the team used an AI-driven protein model to successfully design and construct a mutant MxV-G. The mutated MxV-G eliminates the infectivity to non-T cells while retaining its membrane-fusion-mediating activity. By introducing different T-cell targeting modules, its infectivity to T cells is restored, achieving precise targeting and improving the safety and efficacy of treatment..

为了消除MxV-G的天然趋向性并增强其特异性，团队利用人工智能驱动的蛋白质模型成功设计并构建了突变型MxV-G。该突变型MxV-G在保留其介导膜融合活性的同时，消除了对非T细胞的感染能力。通过引入不同的T细胞靶向模块，恢复了其对T细胞的感染性，实现了精准靶向，并提升了治疗的安全性与有效性。

Next-Generation T-Cell Targeting Molecules: Upgrading Specificity and Anti-Tumor Activity

下一代T细胞靶向分子：提升特异性和抗肿瘤活性

To target T cells precisely, the team engineered multiple T-cell-targeting molecules (TCM). TCM3 demonstrated selective T-cell transduction with no off-target effects and outperformed αCD3/CD80/CD58 (MDF) and αCD3/CD80 in efficiency when paired with different membrane fusion protein variants. CAR-T cells generated by MxV-G-TCM3 showed high specificity across cell lines and reduced T-cell exhaustion markers, supporting sustained activity and improved tumor control.

为了精确靶向T细胞，研究团队设计了多种T细胞靶向分子（TCM）。TCM3展示了选择性的T细胞转导，无脱靶效应，并且在与不同膜融合蛋白变体配对时，其效率优于αCD3/CD80/CD58（MDF）和αCD3/CD80。通过MxV-G-TCM3生成的CAR-T细胞在不同细胞系中表现出高特异性，并降低了T细胞耗竭标志物，支持持续活性并改善肿瘤控制。

In mouse models, this combination exhibited significantly stronger in vivo anti-tumor efficacy compared to αCD3/CD80/CD58..

在小鼠模型中，与αCD3/CD80/CD58相比，这种组合表现出显著更强的体内抗肿瘤效力。

Dr. Hao Ruidong, Partner and Head of the R & D Center at Immunofoco, said, 'CAR-T cell therapy has revolutionized cancer treatment, yet its complex manufacturing and high costs limit accessibility. Our novel in vivo CAR-T platform, powered by lentiviral technology, breaks foreign patent barriers in fusion proteins and T-cell targeting while showing strong in-vitro and in-vivo specificity and efficacy.

免疫焦点公司合伙人兼研发中心主任郝瑞东博士表示：“CAR-T细胞疗法已经彻底改变了癌症治疗，但其复杂的生产工艺和高昂的成本限制了可及性。我们全新的体内CAR-T平台依托慢病毒技术，突破了融合蛋白和T细胞靶向方面的国外专利壁垒，同时展现出强大的体外和体内特异性与疗效。

With simpler manufacturing and lower costs, we aim to make this life-saving treatment accessible to more patients. Moving forward, we'll advance its clinical potential to maximize impact.'.

通过更简单的制造和更低的成本，我们旨在让这种挽救生命的治疗让更多患者可以接受。未来，我们将进一步挖掘其临床潜力，以实现最大化的影响力。

SOURCE Immunofoco Biotechnology

来源：Immunofoco生物技术公司

WANT YOUR COMPANY'S NEWS

想要你公司的新闻

FEATURED ON PRNEWSWIRE.COM?

荣登PRNEWSWIRE.COM？

440k+

44万+

Newsrooms &

新闻编辑室 &

Influencers

影响者

9k+

9k+

Digital Media

数字媒体

Outlets

插座

270k+

27万+

Journalists

记者

Opted In

已选择加入

GET STARTED

开始使用